Q1 2018 EPS Estimates for Atara Biotherapeutics Inc Lifted by William Blair (ATRA)

Atara Biotherapeutics Inc (NASDAQ:ATRA) – Stock analysts at William Blair increased their Q1 2018 earnings per share estimates for Atara Biotherapeutics in a research report issued on Tuesday. William Blair analyst M. Phipps now anticipates that the biotechnology company will post earnings per share of ($0.96) for the quarter, up from their previous forecast of ($0.99). William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for Atara Biotherapeutics’ Q2 2018 earnings at ($0.88) EPS, Q3 2018 earnings at ($0.93) EPS, Q4 2018 earnings at ($0.97) EPS, FY2018 earnings at ($3.75) EPS, FY2019 earnings at ($4.16) EPS, FY2020 earnings at ($3.27) EPS, FY2021 earnings at ($2.79) EPS and FY2022 earnings at ($2.33) EPS.

How to Become a New Pot Stock Millionaire

A number of other analysts have also commented on the stock. Jefferies Group upped their price objective on shares of Atara Biotherapeutics from $30.00 to $46.00 and gave the company a “buy” rating in a research note on Monday, March 5th. Citigroup lowered shares of Atara Biotherapeutics from a “neutral” rating to a “sell” rating in a research note on Thursday, February 15th. Canaccord Genuity reaffirmed a “positive” rating and set a $70.00 price objective (up from $47.00) on shares of Atara Biotherapeutics in a research note on Friday, January 19th. BidaskClub raised shares of Atara Biotherapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, January 23rd. Finally, ValuEngine raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $33.80.

Shares of Atara Biotherapeutics stock opened at $39.65 on Thursday. Atara Biotherapeutics has a 52 week low of $11.80 and a 52 week high of $49.90. The company has a market cap of $1,541.39, a PE ratio of -9.94 and a beta of 2.59.

In other news, CFO John Mcgrath sold 32,000 shares of the stock in a transaction that occurred on Friday, December 29th. The shares were sold at an average price of $20.00, for a total value of $640,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Isaac E. Ciechanover sold 2,200 shares of the stock in a transaction that occurred on Thursday, December 28th. The stock was sold at an average price of $15.15, for a total transaction of $33,330.00. Following the completion of the sale, the chief executive officer now directly owns 743,675 shares of the company’s stock, valued at $11,266,676.25. The disclosure for this sale can be found here. Insiders sold 358,597 shares of company stock valued at $11,295,967 over the last three months. 16.20% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC purchased a new stake in shares of Atara Biotherapeutics in the third quarter worth approximately $142,000. Russell Investments Group Ltd. purchased a new stake in shares of Atara Biotherapeutics in the third quarter worth approximately $170,000. Voya Investment Management LLC lifted its position in shares of Atara Biotherapeutics by 16.2% in the second quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 1,651 shares in the last quarter. MetLife Investment Advisors LLC purchased a new stake in shares of Atara Biotherapeutics in the fourth quarter worth approximately $217,000. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Atara Biotherapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock worth $285,000 after purchasing an additional 1,369 shares in the last quarter. 76.88% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Q1 2018 EPS Estimates for Atara Biotherapeutics Inc Lifted by William Blair (ATRA)” was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3294513/q1-2018-eps-estimates-for-atara-biotherapeutics-inc-lifted-by-william-blair-atra.html.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Xact Kapitalforvaltning AB Invests $214,000 in Covanta Holding Corp
Xact Kapitalforvaltning AB Invests $214,000 in Covanta Holding Corp
Wells Fargo & Company MN Acquires 26,626 Shares of Hortonworks
Wells Fargo & Company MN Acquires 26,626 Shares of Hortonworks
Strayer Education  Holdings Boosted by Wells Fargo & Company MN
Strayer Education Holdings Boosted by Wells Fargo & Company MN
Wells Fargo & Company MN Boosts Holdings in Editas Medicine
Wells Fargo & Company MN Boosts Holdings in Editas Medicine
Lydall, Inc.  Holdings Boosted by Wells Fargo & Company MN
Lydall, Inc. Holdings Boosted by Wells Fargo & Company MN
Orchid Island Capital  Stock Rating Upgraded by Zacks Investment Research
Orchid Island Capital Stock Rating Upgraded by Zacks Investment Research


© 2006-2018 Ticker Report. Google+.